secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2021-07-28T23:59:59+00:00
Accession:  0001157523-21-000935
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower
--------------------------------------------------------------------------------

- Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).
- Net debt reduced by $500M to $22.7B; operating cash flow $218M, free cash flow $625M.
- 2021 revenue outlook cut to $16.0-16.4B (prior $16.4-16.8B) citing COVID impact; all other guidance reaffirmed: adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
- AUSTEDO sales grew YoY; AJOVY net sales $70M worldwide; Truxima US market share reached 25%.
- R&D expenses $248M (GAAP), increased 10% YoY, driven by respiratory, biosimilar projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/0001157523-21-000935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/a52467373.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-000935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer